Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. The company develops the technology for isobaric tandem mass tag (TMT) and TMTpro, and manufacture small, protein-reactive chemical reagents; and Elayta, a small molecule inhibitor of beta-amyloid interaction with synaptic receptors that modifies downstream signaling and provides neuroprotective effects. It offers SysQuant and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the most important factor; TMT Calibrator ?combines protein and fluid proteomics to identify tissue proteins with evidenced availability for peripheral detection; PD biomarker discovery; and TMT SRM and Immuno Assay for CDx biomarker validation. The company primarily serves pharmaceutical and biotechnology companies, including academic research. Proteome Sciences plc was incorporated in 1993 and is headquartered in London, the United Kingdom. The company trades on AIM exchange marketplace. The company headquarter is located in United Kingdom. The company was established in the 2005. The company's ISIN is GB0003104196.
TickerPRM
Long NameProteome Sciences PLC
Short NameProteome Sciences
SectorHealthcare
SubsectorDiagnostics & Research
Subsector 2Health Care
CurrencyGBX
ISINGB0003104196